20/20 GeneSystems, Inc.

Lab-Based Diagnostic Testing Powered by AI and Real-World Data

Claim My Business
Technology, Healthcare & Medical
Min Investment
Offering Date
August 21, 2022
Expected Close Date
December 15, 2022
Target Raise
No. Investors
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

20/20 GeneSystems develops and commercializes clinical laboratory tests that are improved with machine learning and real-world data. Through our high-complexity CLIA lab, we offer what is believed to be the first multi-cancer screening blood test in the U.S. costing under $200. In response to the global pandemic, we expanded our CLIA laboratory test menu to include PCR testing. Due to our ability to scale our COVID testing operation, 2021 revenues exceeded $9 million with over $1 million in net profits for the year. This represents a more than 300% increase over 2020 revenues. As a result, we ranked no. 131 on the Inc. 5000 list of America’s fastest-growing companies in 2022. To grow our portfolio of tests, the Company has built a Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first accelerator facility for diagnostics start-ups. Our CLIAx is expected to help fuel our product and revenue growth for the next five years and already has two companies signed up to join.


StartEngine OWNERS Exclusive Click here to learn more

$500+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Friends & Family
Invest within the first 2 weeks and receive a 25% increase in the annual interest rate on Convertible Promissory Notes in this Offering, where by the interest rate will increase from 6% to 7.5%.





$500+ Investment
Tier 1
Receive 1/3 off all 20/20 lab tests for 12 months. (Only if available in your country)

$1,000+ Investment
Tier 2
Receive 1/2 off all 20/20 lab tests for 12 months. (Only if available in your country)

$2,500+ Investment
Tier 3
Receive 1/2 off all 20/20 lab tests for 18 months. (Only if available in your country)

$5,000+ Investment
Tier 4
Receive 1/2 off all 20/20 lab tests for 24 months. (Only if available in your country)

$10,000+ Investment
Tier 5
Receive 1/2 off all 20/20 lab tests for life. (Only if available in your country)

Key Deal Facts

One of the first in a fast growing market: 20/20 GeneSystems is one of the first organizations in the white-hot market for multi-cancer early detection (MCED) screening blood tests and is collecting test outcome data from around the world to help us refine and improve our algorithms and remain a market leader. Since the start of 2022 advancing MCEDs has become a priority for  members of Congress and the  U.S. National Cancer Institute.

Experienced Team: Our CEO previously established strategic partnerships with Fortune 500 companies such as Johnson & Johnson, Eastman Kodak, Abbott Diagnostics and Smiths Detection.  Our Board members have built and sold several successful diagnostics and medtech companies.

Investor backing: Our shareholders include China’s Ping An Ventures, likely the world’s largest Healthcare AI company (300 million users of its mobile diagnostic app) & thousands of investors, as well as the Keiretsu Forum, family offices, and over 8,000 crowd investors.

Management Team / Advisory Board Bios

Jiming Zhou

Chief Operating Officer

Dr. Zhou graduated from sichuan university (china) and served as an associate professor before moving to the U.S., conducting 7 years of academic research at the university of Iowa. Dr. Zhou published 30+ peer-reviewed research papers, awarded multiple grants and patents. In 2005, Dr. Zhou then joined industrial R&D, and led a joint pharmaceutical project with total milestones of $330 million. From 2009, Dr. Zhou managed multiple clinical labs and co-funded 2 companies, worked with many large U.S. and Chinese public and private healthcare institutes in multiple projects.

Michael Lebowitz

Chief Scientific Officer

Dr. Lebowitz has more than 18 years of experience in biomedical research within the biotech industry having previously served as vice president of research at Ariadne Diagnostics, LLC. He has been directly involved in the commercial launch of six cancer diagnostic tests and the research leading up to a pharmaceutical IND approval. Dr. Lebowitz holds a Ph.D. from the Johns Hopkins University School of Medicine in biochemistry, cellular, and molecular biology where he subsequently completed a three-year fellowship in immunology in the department of pathology, division of immunopathology.

Amy Colton

Senior Sales

Amy Colton joined our team as a senior sales representative, focused on the business development and expansion of OneTest sales. Prior to joining us, she has spent her career in marketing and branding, as well as launching flagship brands for companies like Merck and Allergan, as well as several startup diagnostics companies. Ms. Colton graduated with a BFA in graphic design as well as a BFA in art history from the Savannah College of Art and Design.

Ron Baker

Sales Director

Mr. Baker's responsibilities include identifying new business opportunities that will expand our menu of testing and services. He has held senior-level positions in management, operations, and technical and business development with Roche Diagnostics, Corning Life Sciences, Bio Reliance Corporation, International Clinical Labs, and SGS Life Sciences (Belgium). He also helped launch and build Molecular Oncology, Inc., a specialized oncology testing services company.  

Alexis Levy

Senior Sales Representative

Alexis Levy is a senior sales representative focused on the development and expansion of OneTest sales. Prior to being named senior sales representative, she was sales manager at Alpha Biosciences, where she oversaw the entirety of the company’s worldwide sales. Ms. Levy brings with her over 13 years of experience navigating both the biotech and sales industries. She attended Sweet Briar College where she earned a BS in biology.

Anne Shiflett

Director of Finance

Anne Shiflett brings over 30 years of managerial, financial, and accounting experience to our team. With her extensive life science experience in leading the financial management aspects of companies in diagnostics, drug development to contract research, and contract development manufacturing organizations, she brings critical perspectives as a partner on the executive management team.

John Compton

Chairman of the Board of Directors

Mr. Compton has served as Chairman of the Board since July 2016. He has over 30 years of experience in the development and application of molecular biological techniques to answer questions about genetics and epidermal differentiation, and has authored more than 80 publications in the field. Mr. Compton served as Vice-President of BioReference Laboratories from 2007 to 2013. Previously, Mr. Compton was founder, and served as Scientific Director and Co-President of GeneDx Inc, from 2000 to 2006, the assets of which were acquired by BioReference Laboratories (now part of Opko) in September 2006. Mr. Compton also serves as Mayor of the Town of Washington Grove, MD (2000-2008, 2018-present), on the Board of Directors of Quertle Inc, Henderson NV (text search software and data analytics), and chairs the Boards of the non-profit BlackRock Center for the Arts, Germantown MD (education and performing arts center) and the Pinkney Center for Science and Technology at Montgomery College Germantown Campus. Mr. Compton holds B.S. degrees in Physics and Biology from MIT, received his Ph.D. from the University of California, Berkeley, in Biophysics, and was a Staff Scientist at the NIAMS, National Institutes of Health, Bethesda, from 1991-2000. In 2003, he was awarded the Entrepreneur of the Year award by the Technology Council of Maryland.

Richard M. Cohen


Mr. Cohen has served as a member of our board of directors since July 2016. He is an experienced CEO/CFO at public and private companies. His professional experience includes biotech, financial services and diversified media and he maintains excellent contacts with capital financing sources on and off Wall Street. He has been the President of Richard M Cohen Consultants since 1995, a company providing financial consulting services to both public and private companies. From March 2012 to July 2015, he was the Founder and Managing Partner of Chord Advisors, a firm providing outsourced CFO services to both public and private companies. He was the CEO and CFO of CorMedix Inc., Bridgewater, NJ, a publicly traded medical device/biotechnology company with an intrapericardial therapy product targeted to markets in the U.S. and Europe, from 2010 to 2013. He has served on the board of directors and audit committees of Smart for Life, Inc. (2022 to present), Ondas Holdings Inc. (2018 to present), Helix BioMedix, Inc. (2006 to present), CorMedix Inc. (2010 to 2013), and Rodman & Renshaw (2008 to 2012). Mr. Cohen’s academic credentials include an MBA from Stanford University and B.S. with honors from Wharton School, University of Pennsylvania. Mr. Cohen has no relation to Jonathan Cohen.

John W. Rollins


Mr. Rollins has served as a member of our board of directors since November 2017. He has served on multiple boards and chairs the board of directors of the MedStar Southern Maryland Hospital Center (2014 to present). From 2001 to 2010, he taught Entrepreneurship at the George Washington University School of Business and founded the GW New Venture Competition and served as its Director from 2007 to 2014. In 2003, Mr. Rollins founded StreamCenter, Inc., a firm that pioneered online education using video streaming, and served as chair of the board of directors from 2003 to 2008, and CEO from 2008 to 2010. Prior to 2001, he founded and served for three decades as the CEO and chairman of AZTECH Software Corporation (Bethesda, MD), the nation’s first specialized provider of information technology services to non-profit organizations. Mr. Rollins’s board experience has included serving as Trustee of the National Park Trust (Vice Chair and Treasurer) (1990 to present), Director of the MedStar Georgetown University Hospital (Vice Chair) (2002 to 2013), the Washington Hospital Center (Vice Chair and Treasurer) (1977 to 2002), and the U.S. Association for Small Business & Entrepreneurship (2004 to 2006). Mr. Rollins earned his A.B. in Mathematics from Dartmouth and his M.B.A. in Finance from the Stanford University Graduate School of Business.

Michael A. Ross


Dr. Ross has served as a member of our board of directors since July 2016. He has served as the Chairman and CEO of Euclid Systems Corporation (Herndon, VA) since 2015, where he led the growth of this ophthalmic medical device company from $3.1 million to over $20 Million in five years. The bulk of Euclid’s sales are in China and East Asia where Dr. Ross visits 4-5 times per year. Prior to joining Euclid, he was CEO of E-P Therapeutics from 2010 to 2012, and was a Medical and Scientific Advisor to StemCyte, Inc. 2009 to 2010. He is Board-certified in Obstetrics and Gynecology and is a founding member of an OB-GYN-Infertility practice in Northern Virginia from 1980 to 2007. Dr. Ross has been a Clinical Professor of Obstetrics and Gynecology, George Washington University Medical Center since 1979, and has served on the Boards of Directors of several biotech and medical device companies. He has a B.S. in Chemistry and Biology from Dickinson College and an M.D. from George Washington University.

Ming Li


Li Ming is the general manager of Ping An Ventures with 10+ years of experience in private equity investment. In Ping An Ventures, he covers investment opportunities in biotech, medical equipment, medical services and TMT.
Investment cases include Cloudr Group (9955.HK), General Healthy (605186.SH), HuaTong (605196.SH), BEKE.US.
Before joining Ping An Ventures, Li Ming was the executive director in Ping An Bright Fortune Capital, and investment director in Fosun Capital covering medical service and TMT investment business.
Li Ming holds an MBA degree from Cheung Kong Graduate School of Business.
Li Ming was the Executive Director of Ping An Ventures in the past 3 years.
Amount Raised : $231,669
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Research Reports

No reports have been submitted

Become a Reporter